PDS Plus Antibacterial (Polydioxanone) Sterile Synthetic Absorable Surgical Suture

K212380 · ETHICON, Inc. · NEW · Feb 22, 2022 · General, Plastic Surgery

Device Facts

• Record ID: K212380
• Device Name: PDS Plus Antibacterial (Polydioxanone) Sterile Synthetic Absorable Surgical Suture
• Applicant: ETHICON, Inc.
• Product Code: NEW · General, Plastic Surgery
• Decision Date: Feb 22, 2022
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 878.4840
• Device Class: Class 2
• Attributes: Therapeutic, Pediatric

Intended Use

PDS™ Plus Suture is indicated for use in general soft tissue approximation, including use in pediatric cardiovascular tissue where growth is expected to occur. PDS™ Plus Suture is not indicated in adult cardiovascular and neurological tissue. These sutures are particularly useful where the combination of an absorbable suture and extended wound support (up to 6 weeks) is desirable.

Device Story

Sterile, synthetic, absorbable monofilament suture; composed of poly(p-dioxanone) polyester; contains antibacterial agent Irgacare MP (triclosan) to inhibit bacterial colonization. Used by surgeons in clinical settings for soft tissue approximation. Provides extended wound support for up to 6 weeks. Antibacterial efficacy demonstrated against S. aureus, S. epidermidis, MRSA, MRSE, E. coli, K. pneumoniae, and E. cloacae. Device serves as physical closure mechanism; antibacterial component reduces risk of suture colonization.

Clinical Evidence

Bench testing only. In-vitro quantitative attachment assays demonstrated efficacy of triclosan-coated suture in inhibiting colonization of Staphylococcus aureus, Staphylococcus epidermidis, Methicillin-resistant S. aureus, Methicillin-resistant S. epidermidis, Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae.

Technological Characteristics

Monofilament synthetic absorbable suture; material: poly(p-dioxanone) (C4H6O3)n; contains triclosan (max 2360 ug/m); complies with USP requirements for absorbable surgical sutures (except slight diameter oversize); sterile.

Indications for Use

Indicated for general soft tissue approximation, including pediatric cardiovascular tissue where growth is expected. Not indicated for adult cardiovascular or neurological tissue. Useful for procedures requiring absorbable suture with extended wound support (up to 6 weeks).

Regulatory Classification

Identification

An absorbable polydioxanone surgical suture is an absorbable, flexible, sterile, monofilament thread prepared from polyester polymer poly (p-dioxanone) and is intended for use in soft tissue approximation, including pediatric cardiovascular tissue where growth is expected to occur, and ophthalmic surgery. It may be coated or uncoated, undyed or dyed, and with or without a standard needle attached.

Special Controls

*Classification.* Class II (special controls). The special control for the device is FDA's “Class II Special Controls Guidance Document: Surgical Sutures; Guidance for Industry and FDA.” See § 878.1(e) for the availability of this guidance document.

Predicate Devices

• PDS™ Plus Antibacterial (Polydioxanone) Sterile Synthetic Absorbable Surgical Suture (K061037)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo in blue, with the words "U.S. FOOD & DRUG" stacked on top of the word "ADMINISTRATION".

February 22, 2022

Ethicon, Inc. Marife Sevek Sr. Regulatory Affairs Program Lead 1000 Route 202 Raritan, New Jersey 08869

# Re: K212380

Trade/Device Name: PDS Plus Antibacterial (Polydioxanone) Sterile Synthetic Absorable Surgical Suture Regulation Number: 21 CFR 878.4840 Regulation Name: Absorbable Polydioxanone Surgical Suture Regulatory Class: Class II Product Code: NEW Dated: December 17, 2021 Received: December 20, 2021

Dear Marife Sevek:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

{1}------------------------------------------------

requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

for Deborah Fellhauer, RN, BSN Assistant Director DHT4B: Division of Infection Control and Plastic Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K212380

Device Name

PDSTM Plus Antibacterial (Polydioxanone) Sterile Synthetic Absorbable Surgical Suture

#### Indications for Use (Describe)

PDS™ Plus Suture is indicated for use in general soft tissue approximation, including use in pediatric cardiovascular tissue where growth is expected to occur. PDS™ Plus Suture is not indicated in adult cardiovascular and neurological tissue. These sutures are particularly useful where the combination of an absorbable suture and extended wound support (up to 6 weeks) is desirable.

| Type of Use (Select one or both, as applicable) | |
|---------------------------------------------------------------|--------------------------------------------------------------|
| <div> Prescription Use (Part 21 CFR 801 Subpart D) </div> | <div> Over-The-Counter Use (21 CFR 801 Subpart C) </div> |

ption 300 (Part 21 CFR 1301, Subpart B)

_ Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

# ETHICOL N, INC.

Johnson company a

# 510(k) Summary

| Submitter: | Ethicon, Inc., a Johnson & Johnson Company<br>1000 Route 202<br>Raritan, New Jersey 08869<br>USA |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Marife Sevek<br>Sr. Regulatory Affairs Program Lead<br>Phone: [phone]<br>Fax: [phone]<br>E-mail: [e-mail] |
| Date Prepared: | February 14, 2022 |
| Device Trade Name: | PDS™ Plus Antibacterial (Polydioxanone) Sterile Synthetic<br>Absorbable Surgical Suture |
| Device Common Name: | Suture, Surgical, Absorbable, Polydioxanone |
| Class: | II |
| Classification Name: | Absorbable Polydioxanone Surgical Suture<br>(21 CFR 878.4840) |
| Product Code: | NEW |

# Predicate Device:

| Predicate Device | 510(k) Number |
|------------------------------------------------------------------------------------------|---------------|
| PDSTM Plus Antibacterial (Polydioxanone)<br>Sterile Synthetic Absorbable Surgical Suture | K061037 |

{4}------------------------------------------------

# Device Description:

PDS™ Plus Antibacterial Suture is a sterile synthetic absorbable monofilament suture made from the polyester poly (p-dioxanone). The empirical molecular formula of the polymer is (C4H6O3)n.

PDS™ Plus Antibacterial Suture is available undyed and dyed with D&C Violet No. 2

PDS™ Plus Antibacterial Suture contains Irgacare®† MP (triclosan), a broad spectrum antibacterial agent, at no more than 2360 ug/m.

# Indications for Use:

PDS™ Plus Suture is indicated for use in general soft tissue approximation, including use in pediatric cardiovascular tissue where growth is expected to occur. PDS™ Plus Suture is not indicated in adult cardiovascular and neurological tissue. These sutures are particularly useful where the combination of an absorbable suture and extended wound support (up to 6 weeks) is desirable.

# Summary of Technological Characteristics and Performance:

The subject device has the same technological characteristics as the predicate device. Like the currently marketed predicate device, it is a sterile, monofilament synthetic absorbable suture that complies with the requirements of the United States Pharmacopoeia (USP) for absorbable surgical sutures except for a slight oversize in diameter.

Like the currently marketed predicate device. PDS™ Plus Antibacterial Suture, the subject device will continue to be available as a suture product with Irgacare®† MP (triclosan), an antibacterial agent.

Using in vitro studies. Ireacare@t MP (triclosan) in PDS™ Plus Antibacterial Suture has been shown to inhibit colonization of the suture by Staphylococcus aureus, Staphylococcus epidermidis, Methicillin-resistant S. aureus, Methicillin-resistant S. epidermidis, Escherichia coli, and Klebsiella pneumoniae, and Enterobacter cloacae.

# Substantial Equivalence:

The subject device is identical to the predicate device in terms of material, construction, specification, manufacturing, and sterilization process. The subject device and currently marketed device differ only in the labeling (Instruction for Use and device box). The Performance/Actions section in the Instructions for Use of the subject device was revised to include in-vitro effectiveness against one an additional microorganism, Enterobacter cloacae. This was demonstrated through quantitative in-vitro attachment assay which demonstrates efficacy of the antibacterial suture surface to prevent bacterial colonization against Enterobacter cloacae. The efficacy is reported as a log difference in attached bacteria between treated and untreated suture controls. Additionally, the Indication statement in the Instructions for Use of the subject device were revised to remove ophthalmic surgery. Minor changes to the package label

{5}------------------------------------------------

of the subject devices also includes a new descriptor and icon to allow customers to easily distinguish between Ethicon PDS™ Suture and Ethicon PDS™M Plus Antibacterial Suture.

## Conclusion:

There are no physical or technological characteristic changes to the currently marketed predicate device. The proposed labeling changes for the subject device have been shown to be appropriate for its intended use based on the test result that was submitted. Therefore, the subject device is substantially equivalent to the predicate device.

* Trademark Irgacare® : MP (triclosan) "Registered Trademark of BASF Group"